ReviewThe EPMA journal2017
Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.
Review in The EPMA journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review.International journal of molecular sciences · 2023Pooled it
- The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.Journal of neural transmission (Vienna, Austria : 1996) · 2019Pooled it
- Applications, Challenges, and Future Perspectives of Artificial Intelligence in Psychopharmacology, Psychological Disorders and Physiological Psychology: A Comprehensive Review.Journal of pharmacy & bioallied sciences · 2025Review
- Dynamic Model of Serotonin Presynapse and Its Application to Suicide Attempt in Patients with Bipolar Disorder.International journal of molecular sciences · 2025Article
- Multi-omics approaches for understanding gene-environment interactions in noncommunicable diseases: techniques, translation, and equity issues.Human genomics · 2025Review
- Attitudes towards a multimodal precision medicine algorithm for predicting treatment response in depression: findings from a large cross-sectional European survey.Frontiers in psychiatry · 2025Article
- Exploring the effects of aerobic and resistance exercise on mood-related symptoms and EEG activity.Frontiers in human neuroscience · 2025Article
- Exploring potential working mechanisms of accelerated HF-rTMS in refractory major depression with a focus on locus coeruleus connectivity.European psychiatry : the journal of the Association of European Psychiatrists · 2024Article
- Treatment-resistant depression: molecular mechanisms and management.Molecular biomedicine · 2024Review
- Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder.Molecular psychiatry · 2023Article
- DNA Methylation Patterns in Relation to Acute Severity and Duration of Anxiety and Depression.Current issues in molecular biology · 2023Article
- Early antidepressant treatment response prediction in major depression using clinical and TPH2 DNA methylation features based on machine learning approaches.BMC psychiatry · 2023Article
- Association of Polygenic Score and the involvement of Cholinergic and Glutamatergic Pathways with Lithium Treatment Response in Patients with Bipolar Disorder.Research square · 2023Article
- Application of Pharmacogenomics Testing in a Community-based Facility.Hospital pharmacy · 2023Article
- Divergent Directionality of Immune Cell-Specific Protein Expression between Bipolar Lithium Responders and Non-Responders Revealed by Enhanced Flow Cytometry.Medicina (Kaunas, Lithuania) · 2023Article
- Comparative serum proteomic analysis of a selected protein panel in individuals with schizophrenia and bipolar disorder and the impact of genetic risk burden on serum proteomic profiles.Translational psychiatry · 2022Article
- Article
- Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.BMC medicine · 2022Article
- Antidepressant Treatment and Manic Switch in Bipolar I Disorder: A Clinical and Molecular Genetic Study.Journal of personalized medicine · 2022Article
- Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized medicine (personalized psychiatry in a specific setting) is a new model towards individualized care, in which knowledge from genomics and other omic pillars (microbiome, epigenomes, proteome, and metabolome) will be combined with clinical data to guide efforts to new drug development and targeted prescription of the existing treatment options. In this review, we summarize pharmacogenomic studies in mood disorders that may lay the foundation towards personalized psychiatry. In addition, we have discussed the possible strategies to integrate data from omic pillars as a future path to personalized psychiatry. So far, the progress of uncovering single nucleotide polymorphisms (SNPs) underpinning treatment efficacy in mood disorders (e.g., SNPs associated with selective serotonin re-uptake inhibitors or lithium treatment response in patients with bipolar disorder and major depressive disorder) are encouraging, but not adequate. Genetic studies have pointed to a number of SNPs located at candidate genes that possibly influence response to; (a) antidepressants
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.